Berger, Joachim

[["dc.bibliographiccitation.firstpage","215"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Developmental Dynamics"],["dc.bibliographiccitation.lastpage","221"],["dc.bibliographiccitation.volume","234"],["dc.contributor.author","Mueller, M."],["dc.contributor.author","Berger, Joachim"],["dc.contributor.author","Gersdorff, Nikolaus"],["dc.contributor.author","Cecconi, F."],["dc.contributor.author","Herken, R."],["dc.contributor.author","Quondamatteo, Fabio"],["dc.date.accessioned","2018-11-07T10:56:02Z"],["dc.date.available","2018-11-07T10:56:02Z"],["dc.date.issued","2005"],["dc.description.abstract","Apoptosis is an essential ubiquitous process that controls the duration of the life span of cells, thus playing a crucial role in morphogenetic, histogenetic, and phylogenetic developmental processes. Apaf1 (apoptosis protease activating factor 1) is one of the central mediators of the intrinsic apoptotic pathway and a part of the apoptosome, which activates procaspase-3 and promotes cell death. Gene knockout of Apaf1 in mice leads to late embryonic lethality with malformations such as the persistence of interdigital webs and hyperplasia of brain and retina. Therefore, Apaf1 is generally believed to play a crucial role in developmental apoptosis and have a widespread expression. However, its pattern of expression in early development remains unknown. To specify whether Apaf1 indeed plays this key role, we investigated the pattern of gene expression for Apaf1 in mouse embryos on day 7,9, and 12 of development. Our results show, that gene expression for Apafl first occurs within the embryo between day 7 and 9 of development, becoming more widespread toward day 12 and then includes structures, such as yolk sac, mesenchyme, cartilage, heart anlage, otic vesicle, peridermis, and anlagen of the spinal ganglia and vertebral bodies. Our results also show that gene expression for Apaf1 is not ubiquitous in early mouse development. This finding indicates that cell death processes are independent of or less dependent on Apaf1 during this time. Of interest, an active gene expression for Apafl is also present in organ anlagen such as heart or intestine, in which no obvious phenotype is seen after Apafl deletion. This finding suggests a possible role for Apafl in such anlagen as a putative alternative compensatory pathway, which could he switched on in the case of defects in the mediators that are normally involved in such organs. (c) 2005 Wiley-Liss, Inc."],["dc.description.sponsorship","Telethon [TCP99038]"],["dc.identifier.doi","10.1002/dvdy.20534"],["dc.identifier.isi","000231353700022"],["dc.identifier.pmid","16086359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49920"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1058-8388"],["dc.title","Localization of Apafl1 gene expression in the early development of the mouse by means of in situ reverse transcriptase-polymerase chain reaction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","23"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ZEITSCHRIFT FUR PSYCHOSOMATISCHE MEDIZIN UND PSYCHOTHERAPIE"],["dc.bibliographiccitation.lastpage","37"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Leichsenring, F."],["dc.contributor.author","Dumpelmann, M."],["dc.contributor.author","Berger, J."],["dc.contributor.author","Jaeger, Ulrich"],["dc.contributor.author","Rabung, Sven"],["dc.date.accessioned","2018-11-07T08:50:12Z"],["dc.date.available","2018-11-07T08:50:12Z"],["dc.date.issued","2005"],["dc.description.abstract","Objectives: At the Tiefenbrunn hospital, patients suffering from severe psychiatric and psychosomatic disorders are treated. The treatment concept is psychodynamically oriented. Psychopharmacological treatments are included if necessary. This article reports the results of the treatment of a sample of patients with schizophrenic and other psychotic disorders (ICD-10: F20-F25). Methods: An unselected sample of N = 33 patients was studied upon admission and before discharge with a set of routinely administered standardized instruments. Results: According to the data, all of these patients were severely disturbed: Upon admission to the clinic, they showed high pathological values in the Beeintrachtigungs-Schwere-Score (degree of impairment score; Schepank 1995), the Symptom Checklist SCL-90-R (Franke 1995), the Inventory of Interpersonal Problems (Horowitz et al. 1994), as well as a high degree of comorbid disorders. A comparison of the data at admission and at discharge shows that these patients improved significantly and substantially concerning symptoms, interpersonal problems, contentedness with life and individually formulated target problems. Discussion: The results of the present study are discussed with regard to both the treatment of psychotic patients and the results of other studies."],["dc.identifier.isi","000227951500003"],["dc.identifier.pmid","15834838"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21646"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Vandenhoeck & Ruprecht"],["dc.relation.issn","1438-3608"],["dc.title","Results of inpatient psychiatric and psychotherapeutic treatment of patients with schizophrenias, schizoaffective and other psychotic disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","653"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","656"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Berger, J."],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T08:45:02Z"],["dc.date.available","2018-11-07T08:45:02Z"],["dc.date.issued","2005"],["dc.description.abstract","Background: Sinonasal Teratocarcinosarcoma (SNTC) is a very unusual and aggressive neoplasm characterized by the combination of malignant teratoma and carcinosarcoma features. We present the first case of malignant SNTC treated with individualized multimodal therapy including a histology-specific chemotherapy. Case Report: A 31-year-old man presented with an obstruction of the right pansinus. Histology showed an SNTC with major parts of small cell, poorly differentiated carcinoma and a small proportion of highly differentiated embryonal rhabdomyosarcoma. An operation was performed followed by intraoperative application of a 5-FU ointment. Adjuvant chemotherapy with cisplatin, etoposid and ifosfamid were given in regard to the major components of this heterogeneous tumor. Radiotherapy up to 59.4 Gy was applied. Conclusion: 36 months after the end of therapy, there is no sign of tumor recurrence or metastasis in our patient. We suggest that surgery, radiotherapy and a histology-specific multidrug chemotherapy seems to be a therapeutic approach that is appropriate for this heterogeneous tumor."],["dc.identifier.doi","10.1159/000089146"],["dc.identifier.isi","000233952500007"],["dc.identifier.pmid","16330889"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20335"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","0378-584X"],["dc.title","Rationale for individualized therapy in sinonasal teratocarcinosarcoma (SNTC): Case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","98"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Human Mutation"],["dc.bibliographiccitation.lastpage","98"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Zoll, Barbara"],["dc.contributor.author","Petersen, Lars"],["dc.contributor.author","Lange, Katrin"],["dc.contributor.author","Gabriel, Peter"],["dc.contributor.author","Kiese-Himmel, Christiane"],["dc.contributor.author","Rausch, Peter"],["dc.contributor.author","Berger, Joachim"],["dc.contributor.author","Pasche, Bastian"],["dc.contributor.author","Meins, Moritz"],["dc.contributor.author","Laccone, Franco"],["dc.date.accessioned","2021-06-01T10:50:43Z"],["dc.date.available","2021-06-01T10:50:43Z"],["dc.date.issued","2002"],["dc.identifier.doi","10.1002/humu.9098"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86765"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1098-1004"],["dc.relation.issn","1059-7794"],["dc.title","Evaluation of Cx26/GJB2 in German hearing impaired persons: mutation spectrum and detection of disequilibrium between M34T (c.101T>C) and -493del10"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]